NCT00215410
Completed
Phase 2
Study in Patients With Asthma
Dey1 site in 1 country36 target enrollmentSeptember 22, 2005
ConditionsAsthma
DrugsFormoterol Fumarate
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Dey
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Measure of lung function
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children with a history of asthma
- •Written guardian approval
Exclusion Criteria
- •Current or recent asthma exacerbation, requiring hospitalization
- •History of smoking
- •Debilitating or systemic and/or life-threatening diseases.
Outcomes
Primary Outcomes
Measure of lung function
Secondary Outcomes
- Change in lung function, as well as vital signs
- Physical Exam results, AE reporting, etc
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215397Dey16
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215358Dey32
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215371Dey32
Completed
Phase 3
Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)AsthmaNCT00092144Organon and Co500
Completed
Phase 3
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe AsthmaAsthmaNCT00393952SkyePharma AG557